[Disclosure] Alteogen (196170) to Host AGM on Mar 31: Approving KRW 20B Dividend & Establishing Audit Committee

Source: Financial Supervisory Service DART / 2026-03-16

Disclosure Type: Decision on Convening of General Meeting of Shareholders

💡 3-Second Summary

Alteogen, a leading Korean biotech company, will hold its Annual General Meeting on March 31 to approve a KRW 20 billion dividend (KRW 371 per share) and amend its articles of incorporation to establish an Audit Committee for enhanced corporate governance.

📊 1. [Summary of Key Disclosure Content and Major Figures]

• AGM Date & Venue: March 31, 2026, at 09:00 KST, Grand Ballroom (1F), Daejeon Convention Center, Daejeon, Korea
• Record Date for Voting Rights: December 31, 2025
• Key Agenda Items:
  1. Approval of FY2025 (18th Term) Financial Statements & Dividend: Total dividend amount of KRW 20,003,180,288 (Proposed KRW 371 per share)
  2. Partial Amendments to the Articles of Incorporation: Reflecting the revised Commercial Act and establishing the Audit Committee
  3. Election of Directors: Re-appointment of Executive Director Hang-Yeon Kim (CFO & Vice President); New appointment of Outside Directors as Audit Committee members (Seok-Ki Kim, Sung-Kon Ryu, Sang-Chul Lee)
  4. Other Agendas: Approval of the ceiling on director remuneration, reduction of capital surplus for transfer to retained earnings, approval of retirement allowance regulations for executives, and approval of treasury stock holding/disposition plans

📈 2. [Expert Insight: Financial Implications for Investors]

This AGM announcement indicates that along with its quantitative growth, Alteogen is substantially upgrading its internal controls and corporate governance to align with global standards.

The most noteworthy agendas are the establishment of the Audit Committee and the transfer of capital surplus to retained earnings. Under the Korean Commercial Act, listed companies with total assets of KRW 2 trillion or more are legally required to set up a statutory Audit Committee. Alteogen’s move to establish this committee and appoint qualified outside directors implies that the company is transitioning its corporate structure to match its increased market size. Furthermore, the reduction of capital surplus to boost retained earnings is a tactical financial arrangement that secures distributable income, potentially paving the way for sustainable or enhanced shareholder return policies in the future.

The proposed total dividend of approximately KRW 20 billion (KRW 371 per share) is expected to be finalized during the meeting. The re-appointment of current CFO Hang-Yeon Kim ensures the continuation of stable financial management and the oversight of ongoing global licensing deals. While the enhancement of corporate transparency is likely to attract positive interest from foreign and institutional investors in the long run, investors should continue to monitor whether these new governance mechanisms effectively manage administrative risks as intended.

📝 Editor’s Commentary (by K-STOCK Editor)

Alteogen is finally adopting the institutional framework suited for a large-cap corporation. This upcoming AGM is more than just an event to approve a cash payout; it marks a strategic inflection point where the company secures long-term shareholder return capacity through capital surplus adjustments and installs a sophisticated monitoring apparatus via the new Audit Committee. The recruitment of heavyweights, such as Sung-Kon Ryu, former Director General of the Korea Exchange, as an outside director sends a clear signal of transparency to the market. This meeting will show whether Alteogen can successfully transition from a tech-driven biotech into a structurally mature global enterprise.

📢 Disclaimer & Source Information

Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.